With various treatment protocols applied in different studies, patients were able to gain 6.1–10.3 Early Treatment Diabetic Retinopathy Study (ETDRS) letters of vision in 1 year. The superior effectiveness over laser photocoagulation in improving visual acuity and reducing edema in DME has been demonstrated in several clinical trials ( 3– 7). 41% p = 0.015).Ĭonclusions: After 2-year ranibizumab treatment for DME, better visual and anatomical improvement and less recurrence of macular edema were achieved in the T&E group, with more injections administered.Ĭurrently, the first-line treatment for diabetic macular edema (DME), a condition that leads to severe visual impairment in 28–29% of patients with diabetes mellitus ( 1), is anti-vascular endothelial growth factor (VEGF) therapy ( 2). 6.2 ± 2.0 p < 0.001), while the PRN group had more recurrence of macular edema than the T&E group (71 vs. During the 2-year treatment periods, the T&E group received more injections than the PRN group (11.0 ± 3.2 vs.
The T&E group had a higher proportion of patients with BCVA gain ≥ 15 letters at months 18 ( p = 0.015) and 24 ( p = 0.029) than the PRN group. The mean CFT reduction was 145.5 ± 127.3 and 97.3 ± 152.5 μm in the T&E and PRN groups at 2 years ( p = 0.035), respectively. Results: The average BCVA gain in the T&E and PRN groups was 16.2 and 7.6 ETDRS letters at 2 years ( p = 0.011), respectively. BCVA and CFT changes, number of injections and recurrence of macular edema over 2 years were compared between the groups. Methods: We retrospectively enrolled 34 patients (34 eyes) with DME treated with ranibizumab using the T&E regimen, and 34 patients (34 eyes) treated with ranibizumab using the PRN regimen and matched to cases in the treat-and-extend group by baseline best-corrected visual acuity (BCVA) and central foveal thickness (CFT). Purpose: To compare 2-year treatment outcomes of ranibizumab using treat-and-extend (T&E) or pro re nata (PRN) regimens for diabetic macular edema (DME) in clinical settings. 3College of Medicine, National Taiwan University, Taipei, Taiwan.2College of Medicine, Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan.1Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan.Tso-Ting Lai 1,2, Ta-Ching Chen 1, Chang-Hao Yang 1,3, Chung-May Yang 1,3, Tzyy-Chang Ho 1 and Yi-Ting Hsieh 1 *
0 kommentar(er)
